Biogen (NASDAQ:BIIB) reported Q1 EPS of $3.62, $0.76 worse than the analyst estimate of $4.38. Revenue for the quarter came in at $2.53 billion versus the consensus estimate of $2.5 billion.
- Announces CEO Transition
- Reaffirms FY Guidance
Biogen (NASDAQ:BIIB) reported Q1 EPS of $3.62, $0.76 worse than the analyst estimate of $4.38. Revenue for the quarter came in at $2.53 billion versus the consensus estimate of $2.5 billion.